This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07845500 |
|---|---|
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Pfizer |
| Enrollment | 660 participants |
| Design | Not stated |
| Conditions | Obesity; Overweight |
| Interventions | Semaglutide; Berobenatide; Tirzepatide |
| Start | Sep 30, 2026 |
| Primary completion | Feb 16, 2028 |
| Study completion | Not stated |
| Results posted | Not yet |
| Registry last updated | Not stated |
Source: ClinicalTrials.gov (U.S. National Library of Medicine). See the trial changes feed for what has changed recently.
More from Pfizer
- VESPER-OSA 2: sleep apnea without airway pressure therapy (Phase 3 NCT07881757)
- Once-monthly berobenatide in Chinese adults (Phase 3) (Phase 3 NCT07874633)
- VESPER-JW: once-weekly berobenatide in Japan (Phase 3 NCT07794761)
- VESPER-JM: once-monthly berobenatide in Japan (Phase 3 NCT07794774)
Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.